TX-MARY-KAY
22.3.2022 22:58:11 CET | Business Wire | Press release
Good things come in trees. Following International Day of Forests and World Tree Day, Mary Kay Inc. , a global leader in corporate stewardship and sustainability, is releasing a report detailing its long-standing partnership with the Arbor Day Foundation . Together, Mary Kay Inc. and the Arbor Day Foundation have planted over 1.2 million trees across the globe, making a measurable impact on climate change, CO2 emissions, and reforestation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005134/en/
“Globally, around 18 million acres of trees are lost each year,” said Deborah Gibbins , Chief Operating Officer at Mary Kay Inc. “To raging wildfires, insects, disease, climate change, and more, the need for reforestation is dire. Mary Kay has a footprint in markets around the world—so we must do what we can to protect it. Our partnership with the Arbor Day Foundation allows us to provide a more sustainable future for generations to come.”
Mary Kay’s latest trees report, which can be found linked below on MaryKayGlobal.com, details three cumulative benefits to planting trees through the work the partnership has completed so far.
-
Carbon:
Planting, protecting, and managing trees absorbs carbon. As trees grow, carbon is removed from the atmosphere into trunks, roots, and branches.
- Metric Tons of CO2 Sequestered to Date: 1,018,021
-
Water:
Trees and forests play a vital role in water quality and quantity. Healthy trees and forests reduce soil erosion, filter stormwater and agricultural irrigation, enhance rainfall infiltration, and reduce surface runoff
- Gallons Avoided Water Runoff: 81,902,445 (equal to 930,710 people with clean water)
-
Air:
Trees produce oxygen that we breathe. In addition, trees remove air pollution by lowering air temperature, by releasing water into the atmosphere, and by filtering particulates.
- Tons of Air Pollutants Removed: 4,236
In 2021, Mary Kay Inc. completed six main planting projects in partnership with the Arbor Day Foundation. These included:
- 7,000 trees in Brazil’s Indigenous Fire Recovery Project
- 26,496 trees in the Mississippi River Valley
- 49,004 trees in Florida’s Tyndall Air Force Base
- 7,500 trees in China’s Gansu Province and Inner Mongolia Forests
- 5,000 trees in Cajamarca and Amazonia, Peru
- 5,000 trees in Germany’s Insect Restoration Forests.
In 2022, Mary Kay plans to plant in China, Brazil, Madagascar, and Florida.
In addition to their partnership with the Arbor Day Foundation, Mary Kay served as the executive producer for Forest of Hope , a documentary journey that highlights the battle to save our planet from the impending threats of climate change and destructive human behavior. In partnership with Media One and the Nature Conversancy, Mary Kay visited Monterrey, Mexico, to shed light on a group of female entrepreneurs who are focused on restoring a local species of trees and ecosystems. The film debuted in 2021 and is scheduled to show at upcoming film festivals.
To view the full Mary Kay Inc. / Arbor Day Foundation report, click here .
About Mary Kay Inc.
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn or follow us on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005134/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
